RGNX vs. ADPT, IBRX, ADMA, NVAX, ADAP, SANA, AMAM, CABA, AXLA, and VALN
Should you be buying REGENXBIO stock or one of its competitors? The main competitors of REGENXBIO include Adaptive Biotechnologies (ADPT), ImmunityBio (IBRX), ADMA Biologics (ADMA), Novavax (NVAX), Adaptimmune Therapeutics (ADAP), Sana Biotechnology (SANA), Ambrx Biopharma (AMAM), Cabaletta Bio (CABA), Axcella Health (AXLA), and Valneva (VALN). These companies are all part of the "biological products, except diagnostic" industry.
REGENXBIO vs.
REGENXBIO (NASDAQ:RGNX) and Adaptive Biotechnologies (NASDAQ:ADPT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, community ranking, earnings and media sentiment.
In the previous week, REGENXBIO had 2 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 4 mentions for REGENXBIO and 2 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 1.20 beat REGENXBIO's score of 1.13 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media.
Adaptive Biotechnologies has a net margin of -100.69% compared to REGENXBIO's net margin of -282.72%. Adaptive Biotechnologies' return on equity of -43.10% beat REGENXBIO's return on equity.
Adaptive Biotechnologies has higher revenue and earnings than REGENXBIO. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.
REGENXBIO has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Comparatively, Adaptive Biotechnologies has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500.
REGENXBIO currently has a consensus target price of $35.00, suggesting a potential upside of 104.56%. Adaptive Biotechnologies has a consensus target price of $12.25, suggesting a potential upside of 141.62%. Given Adaptive Biotechnologies' higher possible upside, analysts plainly believe Adaptive Biotechnologies is more favorable than REGENXBIO.
88.8% of REGENXBIO shares are held by institutional investors. Comparatively, 94.3% of Adaptive Biotechnologies shares are held by institutional investors. 13.6% of REGENXBIO shares are held by insiders. Comparatively, 5.2% of Adaptive Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
REGENXBIO received 327 more outperform votes than Adaptive Biotechnologies when rated by MarketBeat users. Likewise, 66.61% of users gave REGENXBIO an outperform vote while only 55.84% of users gave Adaptive Biotechnologies an outperform vote.
Summary
Adaptive Biotechnologies beats REGENXBIO on 10 of the 18 factors compared between the two stocks.
Get REGENXBIO News Delivered to You Automatically
Sign up to receive the latest news and ratings for RGNX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding RGNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
REGENXBIO Competitors List
Related Companies and Tools